Merck Sharp + Dohme Corp.

Jinglai Hao

Bin Hu

Joseph A Kozlowski

Wensheng Yu

Dahai Wang

Bin Zhong

Craig Alan Coburn

Ling Tong

Qun Dang

William K Hagmann

Ravi P Nargund

Michael P Dwyer

Hubert B Josien

Lei Chen

Bandarpalle B Shankar

Jason M Cox

John S Debenham

Cheng Zhu

Purakkattle J Biju

Wei Wei

Derun Li

Linus S Lin

Bing Li

De-Yi Yang

Kartik M Keertikar

Christopher W Plummer

Zhengxia Chen

Razia Rizvi

Deyou Sha

Tao Ji

Timothy Allen Blizzard

Thomas A Bara

Ping Lan

Oleg B Selyutin

Zhong Lai

Jae-Hun Kim

Hyunjin M Kim

Zhongxiang Sun

Murali Rajagopalan

Mingxiang Cui

W Michael Seganish

Chunrui Sun

Zhe Feng

Zhixin Lei

Shuai Zan

Thomas Bara

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. 

Hydroxy isoxazole compounds useful as GPR120 agonists

A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject. 

Hepatitis C virus inhibitors

The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', RR, Rand Rare as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', RRand Rare as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient. 

Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases

The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A', R, R, R, R, R, and Rare defined herein. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The present invention also relates to pharmaceutical compositions comprising at least one Fused Tetracyclic Heterocyclic Compound, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines, and methods of using the Fused Tetracyclic Heterocyclic Compounds for treating or preventing HCV infection in a patient. 

Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

Growing community of inventors

Shanghai, China

Jinglai Hao